40 likes | 179 Views
The ISAR-TEST-4 study evaluates the three-year efficacy and safety of biodegradable polymer stents against permanent polymer stents, and also compares everolimus-eluting stents (EES) with sirolimus-eluting stents (SES) in real-world patients undergoing percutaneous coronary intervention (PCI). This randomized clinical trial's endpoint includes composite measures of cardiac death, myocardial infarction, and target lesion revascularization (TLR) at three years. Results indicate that biodegradable polymer and permanent polymer drug-eluting stents (DES), as well as EES and SES, demonstrate comparable clinical efficacy and safety profiles.
E N D
ISAR-TEST-4 Objective: to compare the 3-year efficacy and safety of biodegradablepolymerwith permanent polymerstents and of everolimus-eluting (EES) withsirolimus-elutingstents (SES)Study: randomizedclinical trialPopulation: real world patients undergoing PCIEndpoint: composite cardiacdeath, MI, TLR at 3 years
ISAR-TEST-4 Conclusion biodegradablepolymer and permanent polymer DES, and EES or SES have similarclinicalefficacy and safety Byrne JACC 2011;58:1325-31